|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM361102771 |
| 003 |
DE-627 |
| 005 |
20231226084432.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109741
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1203.xml
|
| 035 |
|
|
|a (DE-627)NLM361102771
|
| 035 |
|
|
|a (NLM)37611838
|
| 035 |
|
|
|a (PII)S1521-6616(23)00504-1
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Khan, Amber
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Antiretrovirals to CCR5 CRISPR/Cas9 gene editing - A paradigm shift chasing an HIV cure
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 11.10.2023
|
| 500 |
|
|
|a Date Revised 10.11.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a The evolution of drug-resistant viral strains and anatomical and cellular reservoirs of HIV pose significant clinical challenges to antiretroviral therapy. CCR5 is a coreceptor critical for HIV host cell fusion, and a homozygous 32-bp gene deletion (∆32) leads to its loss of function. Interestingly, an allogeneic HSCT from an HIV-negative ∆32 donor to an HIV-1-infected recipient demonstrated a curative approach by rendering the recipient's blood cells resistant to viral entry. Ex vivo gene editing tools, such as CRISPR/Cas9, hold tremendous promise in generating allogeneic HSC grafts that can potentially replace allogeneic ∆32 HSCTs. Here, we review antiretroviral therapeutic challenges, clinical successes, and failures of allogeneic and allogeneic ∆32 HSCTs, and newer exciting developments within CCR5 editing using CRISPR/Cas9 in the search to cure HIV
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Antiretroviral therapy
|
| 650 |
|
4 |
|a CCR5
|
| 650 |
|
4 |
|a CRISPR/Cas9
|
| 650 |
|
4 |
|a HIV
|
| 650 |
|
4 |
|a ∆32
|
| 650 |
|
7 |
|a Anti-Retroviral Agents
|2 NLM
|
| 650 |
|
7 |
|a CCR5 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Receptors, CCR5
|2 NLM
|
| 700 |
1 |
|
|a Paneerselvam, Nandagopal
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lawson, Brian R
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 255(2023) vom: 15. Okt., Seite 109741
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:255
|g year:2023
|g day:15
|g month:10
|g pages:109741
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109741
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 255
|j 2023
|b 15
|c 10
|h 109741
|